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ABSTRACT Silk is a remarkable biopolymer with a long
history of medical use. Silk fabrications have a robust track
record for load-bearing applications, including surgical threads
and meshes, which are clinically approved for use in humans.
The progression of top-down and bottom-up engineering ap-
proaches using silk as the basis of a drug delivery or cell-loaded
matrix helped to re-ignite interest in this ancient material. This
review comprehensively summarises the current applications of
silk for tissue engineering and drug delivery, with specific ref-
erence to the eye. Additionally, the review also covers emerging
trends for the use of silk as a biologically active biopolymer for
the treatment of eye disorders. The review concludes with fu-
ture capabilities of silk to contribute to advanced,
electronically-enhanced ocular drug delivery concepts.
KEYWORDS Bombyxmori .drugdelivery .eye .ocular . silk
fibroin . tissue engineering
ABBREVIATIONS
PBS Phosphate buffered saline
PEG Polyethylene glycol
RGD Arginine-glycine-aspartic acid
INTRODUCTION
Humans have appreciated silk cloth for millennia for its lus-
trous texture and remarkable physical properties (1). The abil-
ity to unravel the thread from the silk cocoon and weave
fabrics with the cleaned thread has been truly transformative
(1). Repurposing the silk fibre for medical applications
changed the medical landscape (1) ultimately resulting in
sterile silk sutures still in use today (2), especially for del-
icate procedures like eye surgery. Our ability to apply top-
down and bottom-up approaches to generate silk with the
required properties has resulted in an explosion of poten-
tial applications (1,3,4). In particular, our ability to fully
regenerate the silk cocoon into an aqueous silk solution
and to use genetic engineering to produce recombinant
silks with molecularly defined composition. These new ad-
ditions to the silk toolbox now allow the fine-tuning of silk
function by manipulation of silk across all scales, including
primary sequence, chemical functionality, and secondary
and tertiary structure, as well as formatting it from the
nano- to macroscopic scales (1). Recent reviews detail the
current and emerging trends in the use of (recombinant)
silk for biomedical (1,3) and advanced manufacturing (4).
This review now describes the use of silk for the treatment
of eye disorders by closely examining the use of silk for
eye-related tissue engineering applications, as well as for
drug delivery to the eye (Fig. 1).
The eye is enclosed within the skull and anchored by
muscles and tendons; therefore, the spaces around the
eye provide convenient sites that could serve as drug de-
pots for materials such as silk-derived hydrogels (provided
that vision is not impaired and the formulation does not
physically obstruct eyeball rotation). The material could be
moved under the orbital fascia, such as the conjunctiva,
and placed in the space between the globe and the skull
(a subtenon injection) or within the eyeball. The adminis-
tration of subconjunctival injections by nursing staff is a
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common practice in the clinic (5); for example, sustained-
release glaucoma medicine can be administered by
subconjunctival injection. Therefore, acceptance by pa-
tients is likely to be high (6). Canavan and colleagues pro-
vide a useful review of the application of this subtenon
technique in anaesthesia (7). Volumes of around 2 mL
can typically be introduced without problems. Creating
depots more posteriorly might be more desirable to avoid
clearance mechanisms, but this reduces access and could
compromise the vascular system. Retrobulbar injection
(i.e. injection behind the eyeball) has also been practiced
for many years, although it is not without risk (8,9).
Awareness of the risk has been raised by experience with
three-dimensional remoulding of facial tissue conducted by
cosmetic surgeons, who have reported that autologous fat
injection can cause irreversible blindness due to embolic
occlusion of arteries. The alternative is to inject biomate-
rials such as hyaluronate, which can be degraded quickly in
an emergency. For example, Carruthurs and colleagues
have illustrated that retrobulbar injection of high-dose hy-
aluronidase can prevent blindness if carried out in the
short critical window before irreversible retinal hypoxia
occurs (10) following the use of hyaluronic acid based
fillers. Such a safety consideration to remove a matrix safe-
ly in an emergency is an unexpected and valuable attri-
bute. Finally, the potential space is surprisingly large: a
complete peribulbar injection, filling all the space includ-
ing the intraconal fat space can accomodate larger volumes
- typically 6 to 12 mL.
Most studies to date that have investigated the use of silk for
ocular drug delivery and tissue engineering applications have
used everyday silkworm silk (i.e. Bombyx mori silk) (Table I). For
this reason, we first provide a brief background of the B. mori
silk structure (reviewed in more detail in (28)).
Silk Structure
The domesticated B. mori silkworms spin their cocoons from 2
main proteins: silk fibroin and sericin. The silk fibroin protein
is composed of several subunits—the heavy chain, the light
chain and glycoprotein P25 (29)—whereas sericin is a single
hydrophilic protein having a molecular weight ranging from
20 to 400 kDa (30).
The silk fibroin heavy chain is the largest of all the fibroin
subunits, with a molecular weight of approximately 350 kDa
(29). The mechanical strength of the silk fibre is imparted by
the 12 crystalline regions of the silk fibroin heavy chain (31).
These crystalline regions, embedded within an amorphous
matrix, are composed of highly structured β-sheets. The most
abundant silk sequence contributing to these β-sheets is a high-
ly repetitive GAGAGS motif (31,32). The light chain of the
silk fibroin, approximately 25 kDa in size, has no repeating
amino acid sequence and is covalently attached to the heavy
chain by a single disulphide bond at the C-terminal (33).
Although glycoprotein P25 is about the same size as the light
chain (27 kDa) (29), it is not covalently connected to the heavy
chain; instead, it associates with the heavy–light chain com-
plex through hydrophobic interactions (34).
The silk fibroin is assembled from various secondary struc-
tures, including β-sheets, α-helices and turns. Consequently,
its conformation can be impacted by mechanical stresses (i.e.
shear, strain), solution chemistry (i.e. solvents, pH, ions) and
temperature (35). Three conformations—silk I, silk II and silk
III—are recognised for silk fibroin. Silk I consists mostly of α-
helices, whereas the majority of silk II is composed of β-sheets
in the secondary structure. The aqueous solubility is much
higher for native silk I, at approximately 26–30 wt.%
(36,37), than for regenerated silk (detailed below), which typ-
ically aggregates at these high concentrations. The high
Fig. 1 Diagram of a human eye showing expanded corneal layers and retinal layers. Annotated silk fibroin figures indicate the ocular spaces where silk was
studied. Figure adapted from Servier Medical Art.
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solubility of the silk I conformation enables the silk fibroin to
exist as a concentrated solution in the silk gland, where it
awaits spinning into silk II (36). The structure of silk III is less
well understood; however, at an air-water interface, silk III
contains helical structures that function similarly to a surfac-
tant, separating hydrophilic serine residues from hydrophobic
alanine residues at the opposite sides of the interface (38).
The conformation of the silk fibroin can directly impact the
mechanical strength of the resulting silk fibre. For example,
Wang and colleagues showed that ions, such as Na+, K+,
Ca2+ and Cu2+, can alter the conformation of the silk fibroin,
thereby affecting the fibre strength (39,40). The silk thread is
bifilar because each silk filament is derived simultaneously
from the silkworm’s paired silk glands. Within each gland, a
drop in pH triggers silk self-assembly, which drives the transi-
tion of liquid silk into its fibre format. The two silk filaments
are combined and coated with the glue-like sericin protein
(41), before the silk thread is pulled (i.e. ‘pulltrusion’) (42) from
the spinneret. This inherent self-assembly of silk fibroin, trig-
gered by the aforementioned environment factors (i.e. pH,
ions, etc.), has been widely exploited to develop novel silk
formats using the regenerated silk fibroin (detailed below);
sericin is removed during the silk fibroin regeneration process.
Sericin – Friend or Foe?
The raw bifilar silk thread contains sericin, which encases and
physically combines the two silk fibroin filaments. Sericin is a
protein with a large number of neutral polar functional
groups. It contributes between 25 and 30% of the cocoon
weight and forms the gummy layer that holds the cocoon
together. Sericin is classified according to its solubility in water
into 3 different categories: sericin A, B and C (from most
soluble to least soluble in aqueous solution) (30). Sericin is
typically removed during raw silk processing, and yielding
about 50,000 tons of sericin in 2002 (43), a figure that is still
quoted as approximate world tonnage in 2017. Small sericin
peptides are soluble in cold-water and are recovered at the
early stages of raw silk processing, whereas the larger sericin
peptides are obtained during hot water degumming of the silk.
As a waste product of the extraction process, sericin is used as
an inexpensive filler for other polymers, including polyure-
thane foam, films and foams that include polyols, catalysts
and blowing agents, where needed.
The toxicity of sericin is often debated, and the diversity of
data suggests that different preparations may yield different
fractions, thereby explaining the observed discrepancies.
Historically, sericin has been attributed to adverse reactions
in humans reported for virgin silk (reviewed in (44)); however,
emerging evidence indicates that sericin is a useful biopolymer
with a favourable biocompatibility. For example, sericin
hydrogels showed a low in vivo allergenic and immunogenic
profile, with a response similar to that observed for silk fibroinTa
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or alginate (45). Aramwit and colleagues (46) described sericin
fractions obtained by different methods, namely heat, acid,
alkali and urea extraction, and confirmed that the starting ma-
terial is a mixture of at least fifteen different polypeptide chains
(47). These authors examined the zeta potential and particle
size of products produced by these different techniques and
determined that the urea-extracted fraction was water soluble,
whereas the fractions produced by other methods were proba-
bly larger hydrocolloids (48). Examination of the viability of an
L929 cell line exposed to different extracts at concentrations up
to 1 mg/mL showed that the urea-extracted fraction had the
greatest toxicity, whereas the other fractions were well tolerated
by the cells at concentrations up to 100 μg/mL (48).
The mulberry leaf (the exclusive diet of B. mori silkworms)
contains many flavonoid antioxidants that become incorpo-
rated into the spun silk and especially into the sericin fraction.
The biological role of these flavonoids may be to provide
chemical protection for the developing moth against pests
while the cocoon provides physical protection. In small ro-
dents, these Bcontaminated^ sericin materials show pharma-
cological effects as diverse as improved stamina and increased
intestinal absorption of metals (49). Tissue regenerative effects
have also been suggested, and the potential of nanofibrous
mats based on silk sericin/PVA electrospun material has been
explored following subcutaneous implantation (50). Data in
mice indicated good biocompatibility and low infection, and
the authors suggested that the mulberry leave derived antiox-
idants within the material might impart superior properties to
those of ‘inert’ dressings. Addition of a purified sericin fraction
to an immortalised corneal cell culture and to an experimental
wound in rats (51) increased the wound healing rate and this
response was suppressed by addition of an ERK inhibitor,
suggesting that sericin promoted phosphorylation of
ERK1/2. However, full wound healing occurred at approxi-
mately the same rate as was observed in the controls. Sericin
appeared to increase the movement of cells, prompting the
authors to look for other cytokine signals that might be affect-
ed. These putative medical effects of sericin have inspired
many other studies with a view to adding sericin to the human
diet. Sericin has also been heavily exploited as an additive in
the cosmetics industry. These diverse benefits might aid in
overcoming the long-standing and serious problem of envi-
ronmental pollution associated with sericin generation by the
silk industry, thereby encouraging further development of uses
for this ‘waste product’ (49).
Biocompatibility and Biodegradation of Regenerated
Silk Fibroin
The mechanical strength of silk makes it an attractive polymer
for biomedical applications, such as suturing and tissue engi-
neering. Silk sutures (44), silk garments to treat dermatological
conditions (1), and silk surgical meshes (SERI® Surgical
Scaffold) (52) are currently the only clinically approved silk
products in Europe and North America (1); these products
utilise the in vivo spun B. mori fibre. However, most studies
reporting the pre-clinical development of silks for ocular ap-
plications utilise regenerated B. mori silk (53) (Table I). Here,
the silk cocoon is processed into aqueous silk fibroin stock
(with similar properties to the native silk stored in the silkworm
silk glands) (54). First, the silk cocoons are cut into small pieces
and then typically boiled in an alkaline solution (e.g. sodium
carbonate) to remove the sericin (53). The resulting silk fibroin
is then dried and the higher-order silk structures are
disassembled with a chaotropic salt (e.g. lithium bromide, gua-
nidine hydrochloride, urea or calcium chloride). The silk fi-
broin solution is dialysed against water to remove the salt,
ultimately yielding an aqueous silk solution (53). Differences
in the processing parameters (e.g. degumming time) can result
in regenerated silk fibroins that vary in molecular weight.
This, in turn, influences silk fibroin performance, including
mechanical strength (55–57).
The regenerated silk fibroin solution typically serves as the
starting material for generating novel silk formats, including
thin films (58). In the eye, the use of silk films is most feasible in
the area of corneal grafting, where the replacement tissue
layer of the diseased cornea is often cultured ex vivo and then
transplanted back into the patient (59). As a substrate, silk
provides a sturdy platform for proliferation of the respective
(stem) cells and their differentiation into the matured tissue
layer required for transplantation.
The biocompatibility and biodegradation of the regenerat-
ed silk fibroin has been evaluated both in vitro and in vivo often
with superior performance than fully synthetic or other bio-
polymer materials (reviewed in (1,60,61)). Silk is not of mam-
malian origin (like other clinically used biomaterials e.g. algi-
nate, chitosan etc.); therefore, foreign body responses to silk-
based implants and suturesmight be expected. Various studies
performed in rodents and large animals to evaluate silk fibroin
biocompatibility across many different formats, including
meshes (52), thin films (19,20), hydrogels (27,45,62), nanopar-
ticles (63–65) and liquid solutions (23,25), have confirmed that
silk fibroin induces no significant adverse responses, thereby
substantiating the claims that silk fibroin is a biocompatible
biopolymer. More importantly, these observations translate
well to humans (1). Of course, universal biocompatibility does
not exist, so dedicated biocompatibility studies are still re-
quired when exploring novel silk applications. Similar consid-
erations apply to the biodegradation of silk fibroin, because
the material format, processing conditions and implantation
site are expected to impact its degradation profile.
Silk Sutures
One silk application that dates back several millennia is its use
as suture material (1). However, a number of adverse reactions
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have been reported for virgin silk sutures (66) (reviewed in
(44)). Furthermore, braided silk sutures could potentially carry
the risk of infection, which is thought to arise due to capillary
movement of fluids and the establishment of a biofilm around
the silk protein fibres. This potential risk of infection can be
mitigated with the application of appropriate coatings, such as
the use of an additional levofloxacin layer. For example, Chen
and colleagues examined the performance of antibacterial
loaded silk sutures in which the silk fibroin strands were
dipped in levofloxacin in a polycaprolactone formula to con-
trol levofloxacin release (67). Bacterial inhibition zones against
E. coli showed complete kill after a 24 h incubation. Today,
synthetic materials, such as Vicryl®, a copolymer made from
90% glycolide and 10% L-lactide, predominate the suture
applications. Nevertheless, the characteristics of silk sutures,
such as knot security and lying flat on the tissue surface, re-
main advantageous. For these reasons, silk sutures are still
used today for specialist eye surgery (1).
Silk for Ocular Tissue Engineering: Corneal Epithelium
Corneal disease is the most common cause of blindness, af-
fecting approximately 27.9 million individuals worldwide (68).
Currently, corneal transplantation remains the only accept-
able treatment to restore visual acuity (59); however, the in-
creasing demand for and limited supplies of donor corneas
from the Eye Bank have created long waiting lists for corneal
transplantation in most developing countries (69). The short-
age of human corneas has led to some major developments in
the field of corneal tissue engineering, particularly in the use of
silk films as substrates to grow corneal cells for ocular surface
reconstruction (70) at any of the 5 layers of the cornea (from
outermost to innermost: the epithelium, the Bowman’s layer,
the stroma, the Descemet’s membrane and the endothelium)
(Fig. 1).
Presently, the preferred surgical membrane for the corneal
epithelium reconstruction is the human amniotic membrane
due to its abilities to inhibit inflammation, tissue scarring and
angiogenesis. However, the use of this membrane has some
drawbacks. Firstly, when compared to other synthetic mem-
branes, such as the silk fibroin, the amniotic membrane has
poor mechanical strength, which creates difficulties in han-
dling. Secondly, the amniotic membrane is semi-transparent,
which can adversely affect light transmission, an important
attribute of the corneal surface. Finally, disease transmission
(e.g. HIV, hepatitis, etc.) is a potential risk because the human
amniotic membrane comes from human donors. The use of
silk fibroin can circumvent these potential issues as demon-
strated in preclinical studies by Liu and colleagues using the
human amniotic membrane as the control (12).
Liu et al. prepared silk fibroin membranes for epithelial cell
sheet generation using B. mori silk fibroin solution casting,
followed by water annealing of the silk film to induce beta-
sheets. The resulting silk fibroin film had a 14 mm diameter
and 40 μm thickness and was a highly transparent film that
could hold its shape after handling. By contrast, the human
amniotic membrane prepared in parallel was semi-
transparent and prone to folding when handled with forceps.
Epithelial cells sheet for subsequent transplantation were gen-
erated by seeding human immortalised corneal epithelial cells
and rabbit primary corneal epithelial cells on both the silk
fibroin membrane and the human amniotic membrane.
Cells seeded on the amniotic membrane differentiated faster
to give a 3-fold higher density after 72 h of cultivation when
compared to the cells seeded on the silk fibroin membrane.
However, after 144 h, the cells seeded on the silk fibroin
membrane achieved the same density as the cells cultured
on the amniotic membrane. The corneal epithelial cells
expressed equivalent amounts of keratin 3 and P63a proteins
irrespective of their culture substrates (12).
The observed higher proliferation rate in cells grown on
human amniotic membrane could be attributed to a more
favourable cell adhesion, which is influenced by surface topog-
raphy as well as the presentation of the RGD peptide (an
arginine-glycine-aspartic amino acid sequence required for
integrin-mediated cell adhesion) among other, yet defined,
factors. Topographic features on the silk surface, specifically
the groove pattern, have been demonstrated to assist in the
orientation of human corneal stromal stem cells and human
corneal fibroblasts during generation of a corneal-like stromal
construct (58,71). The orientation of the stromal cells is nec-
essary for conferring transparency of the cornea while the
coupling of RGD peptide to a silk film surface is necessary
to allow the formation of a confluent layer (11).
Similar to corneal stromal cells, corneal epithelial cells also
appear to respond differently to different topographic features
of silk film surfaces. Cells grown on silk film surfaces with a
parallel line pattern displayed more than 2 fold increase in
focal adhesion localisation than on surfaces with a concentric
ring pattern or on glass controls (13). The study, however, also
found that the presence of a surface pattern affected cell mor-
phology, cell alignment and the cytoskeleton more than just
cell proliferation.
In a separate study, human corneal epithelial cells were
also found to respond distinctly to surfaces with different pitch
and width dimensions (16). Similar to the findings from
Lawrence et al. (13), the authors found that cell morphology
and alignment were most likely to be affected by surface to-
pography. For instance, a nanoscale topography cued the cells
to align perpendicular to the patterned edge, whereas larger
microscale topography cued the cells to align parallel to the
patterned edge. Cell lengths were also 2-fold longer in cells
growing on patterned silk films than on a flat silk film surface.
The authors also noted that although the overall change in
gene expression was similar for all cells grown on surfaces with
different topography, the degree of change in gene expression
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was greater in cells growing on the silk film with nanoscale
topography, and those cells also expressed higher levels of
genes involved in the development of the cytoskeleton (i.e.
paxillin, integrin β1 and vinculin), which is important for focal
adhesion.
Biazar and colleagues performed an in vitro study that di-
rectly compared the utility of silk fibroin versus human amni-
otic membranes for growing human limbal epithelial stem
cells (14). The aim of the study was to assess whether human
limbal stem cells would retain their limbal stem cell character-
istics after being seeded onto either oriented nanofibrous silk
mats, random nanofibrous silk mats, or human amniotic
membranes. The human amniotic membrane served as a pos-
itive control because cells grown on this particular membrane
differentiate and stratify into the appropriate intended corneal
layer (72).
Several biomarkers (i.e. keratin 3 and 12, nuclear protein
P63 and ATP-binding cassette sub-family G member 2) were
monitored to assess the cell types. Keratin 3 and 12 marker
genes are indicators of differentiated epithelial cells (73),
whereas nuclear protein P63 and ATP-binding cassette sub-
family G member 2 genes are indicators of stem cells (74).
After 15 days of in vitro cultivation, cells from all membranes
showed higher expression of nuclear protein P63 and ATP-
binding cassette sub-family G member 2 genes relative to
keratin 3 and 12 expression, suggesting that the cells main-
tained their Bnon-differentiation^ stage after growing on the
membranes for 15 days. However, similar to the findings of
Liu and colleagues (12), cell growth and viability were better
for cells growing on the amniotic membranes than on silk
films. These findings validate the human amniotic membranes
as the clinical standard and suggest that second generation silk
constructs are required to support the growth of corneal
limbal epithelial cells.
In addition to retaining their non-differentiated stem cell
stage, corneal limbal epithelial stem cells, when grown on silk
film substrates, were also able to differentiate into normal
corneal epithelium in a rabbit model of limbal stem cell defi-
ciency (17). Typically, patients with limbal stem cell deficiency
exhibit increased neovascularisation and decreased corneal
clarity (75). These authors successfully replicated the limbal
stem cell deficiency conditions with their rabbit model (17).
The surface roughness and tensile strength of the final silk
films were improved by mixing and subsequent removal of
PEG 400 from the silk fibroin solution. The authors asserted
that this additional PEG 400 treatment was essential to pro-
vide a silk fibroin film with sufficient strength for surgical ma-
nipulation (17). However, in a separate study, Suzuki and
colleagues reported no improvement in the tensile strength
of the resulting silk film following PEG treatment (15). These
conflicting data could be attributed to differences in the pro-
cessing parameters. For example, Suzuki and colleagues gen-
erated samples with a high PEG content (i.e. 1 part 100%
PEG300 to 2 parts 1.78% silk fibroin (15)) whereas Li and
colleagues (17) used substantially less PEG (i.e. 1 part 40%
PEG400 to 100 parts 4% silk fibroin). Li and colleagues
showed that rabbit limbal epithelial stem cells responded best
to tissue explant and single cell-suspension cultivation
methods rather than a cell cluster cultivation method (17).
Cells harvested from tissue explants and single cell-
suspension cultures expressed higher levels of nuclear protein
p63α and the protein ATP-binding cassette, sub-family B,
member 5 (i.e. limbal stem cell markers) than did cells harvest-
ed from cell cluster culture. In the limbal stem cell deficiency
rabbit model, the authors showed that the limbal epithelial
stem cell/silk fibroin grafts inhibited the formation of new
blood vessels and restored the corneal epithelium, providing
evidence that cultured limbal epithelial stem cells can differ-
entiate into normal corneal epithelium to replace a diseased
epithelium (17).
The Third Dimension
Silk fibroin can be utilised as a support material and the
growth and expression of important messenger molecules
can be measured; however, the removal of cells from the ex-
tracellular matrix and monolayer culture during harvesting
can increase apoptosis and the rates of cell death. This phe-
nomenon has been extensively studied during the collection
and transport of pancreatic islet cells from human donors (76).
Three dimensional constructs, by contrast, can serve as artifi-
cial niches; for example, silk presenting the RGD motif assists
in cluster formation and mimics the extracellular matrix (77).
The RGD sequence can be grafted onto B. mori silk using
standard carbodiimide chemistry (78) (because B. mori lacks
the RGDmotif) or, as shown by the Hedhammar group using
recombinant silks, the sequence can be cloned into the repet-
itive part of spider silk 4REpCT protein (79). The pancreatic
islet explant work by Hedhammar and colleagues showed that
it is plausible to transplant insulin secreting islet-like clusters
from mouse and human primary cells grown on a silk foam
into the mouse eye. The transplanted clusters remained
capable of releasing insulin (80) and were vascularised and
innervated within the eye (81).
Silk for Ocular Tissue Engineering: Corneal Stroma
The stroma comprises about 90% of the cornea thickness and
consists mostly of collagens, proteoglycans and cells (82). It is a
complex layer, with highly ordered microstructures that inter-
act with the epithelium layer and nerve cells. Diseases associ-
ated with impaired corneal innervation include corneal ulcers,
which are marked by decreased corneal sensitivity and alter-
ations in the corneal epithelium, nerves, keratocytes and en-
dothelium (83,84). A recent study by Wang and colleagues
focused on the development of a silk corneal scaffold that
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included the epithelium and the stroma, along with innerva-
tion (18). The authors used human corneal stromal stem cells,
human corneal epithelial cells and chicken dorsal root gangli-
on; the latter can interact with human cells and mimic corneal
innervation (85,86). Films were generated by solution casting
of silk fibroin spiked with PEG onto a polydimethylsiloxane
template (either patterned or plain), followed by drying and
water annealing (18). The PEG was then leached from the
samples to generate porous silk films that would ultimately
allow mass transport. The films either contained patterns or
were biofunctionalised by stamping (with keratinocyte growth
factor, hepatic growth factor, epithelium growth factor and
nerve growth factor). Patterned silk films were seeded with
human corneal stromal stem cells, while human corneal epi-
thelial cells were seeded onto the porous silk films. The silk
sponge was seeded with chicken dorsal root ganglion. The
three dimensional corneal tissue model was assembled by
stacking the cell-seeded patterned and plain silk films; these
were then surrounded with the porous silk sponge to provide
innervation. These three-dimensional co-cultures were culti-
vated in either liquid or an air-liquid interface and were then
compared with single cultures (18).
After 28 days of cultivation, the resulting engineered cor-
neal tissue achieved a transparency comparable to that of a
porcine cornea. Due to the simulation of the microenviron-
ment within the stroma, cultivation in an air-liquid interface
was deemed more effective than the liquid interface and
attained about a 2-fold increase in axon density.
Furthermore, cultivation of the co-cultures in liquid led to a
decrease in numbers of human corneal stromal stem cells
when human corneal epithelial cells were included in the sys-
tem. This result was not observed when the co-cultures were
cultivated in the air-liquid interface. These findings indicated
that human corneal epithelial cells are more sensitive to the
culture conditions than are human corneal stromal stem cells.
Therefore, the development of a successful scaffold should
preferably incorporate cultivation in an air-liquid interface
as this mimics the natural cornea microenvironment.
Chicken dorsal root ganglion was used to innervate the
synthetic silk fibroin scaffold and innervation was observed
in all co-cultures (18). The complex interactions of different
corneal cells and their extracellular matrix within this silk fi-
broin scaffold showed its potential usefulness as a stroma al-
ternative for the study of drug development, disease interven-
tion and general corneal physiology.
Silk for Ocular Tissue Engineering: Corneal Descemet
Membrane
Ocular diseases involving the corneal endothelium have often
been addressed by surgical techniques such as Descemet
membrane endothelial keratoplasty and Descemet stripping
automated endothelial keratoplasty (reviewed in (87)). These
procedures involve the transplantation of the patient’s
Descemet membrane, along with the endothelium, with the
donor’s graft. Tissue engineering using silk fibroin could po-
tentially supplant the need for donor grafts. Similar to corneal
epithelial cells and stromal cells, the corneal endothelial cells
can be cultured on silk fibroin substrates, which act like the
Descemet membrane, as shown for the artificial endothelial
graft constructed by Vazquez and colleagues (20). They cast
the silk film from a 5% w/v silk fibroin solution and obtained a
thin film with a thickness of 10 μm. The final silk fibroin film
was water-annealed.
Both human and rabbit corneal endothelial cells have been
successfully cultured on silk fibroin films to form silk fibroin
endothelial grafts (20). These endothelial grafts containing
rabbit corneal endothelial cells were successfully transplanted
into New Zealand white rabbits in a Descemet membrane
endothelial keratoplasty procedure. The rabbit silk fibroin en-
dothelial grafts integrated fully with the corneal tissue and
showed a similar thickness and cell count as observed in the
contralateral cornea. Additionally, no signs of immune rejec-
tion of the endothelial grafts were observed. By contrast, the
corneas of the rabbit control group, which had only the
Descemet membrane peeled off, did not recover and exhibit-
ed oedema throughout the 6-week follow-up period. The
same results were also observed in the rabbit group that re-
ceived the silk fibroin transplant without cultured corneal en-
dothelial cells. This study (20) showed that silk fibroin can be
an effective artificial Descemet membrane for the ex vivo cul-
ture of corneal endothelial cells in preparation for a silk fibroin
endothelial graft.
Silk for Ocular Tissue Engineering: Retinal Bruch’s
Membrane
One of the approaches for treating retinal degeneration
caused by diseases such as age-related macular degenera-
tion involves the transplantation of a monolayer of retinal
pigment epithelial cells (88,89). Exciting advances are be-
ing made in this area; for example, Phase I clinical trials
have shown successful transplantation of human embryon-
ic stem cell-derived retinal pigment epithelium using po-
rous fibronectin-coated polyester membranes (90). These
non-biodegradable membranes were derived from cell cul-
ture Transwells®. However, one of the drawbacks of this
type of procedure is the potential for folding of the retinal
pigment epithelial cell sheet after transplantation and the
persistence of the membrane (89,91). The use of silk fibroin
as a substrate for in vitro proliferation of retinal pigment
epithelial cells can potentially replace the Bruch’s mem-
brane after transplantation.
In the reconstruction of the retina, the material will be
located close to neurological tissue, so biocompatibility of a
thin, mechanically strong support is a key requirement.
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Shadworth and colleagues achieved silk fibroin beta-sheet for-
mation by water annealing at room temperature prior to
seeding with cells (19). The cells on the 3 μm thick silk fibroin
film exhibited characteristics of matured retinal pigment epi-
thelial cells, such as cobblestone morphology accompanied by
pigmentation, within a 12-week timeframe (19). Over this
time, the retinal pigment cells proliferated and slowly
established dense surface microvillous structures (19). Thema-
tured retinal pigment epithelium cells also developed a capac-
ity to perform phagocytosis as well as to secrete essential
growth factors, such as pigment epithelium-derived factor
and vascular endothelial growth factor. Although this study
did not evaluate the in vivo implantation of the synthetic
Bruch’s membrane, the reported data indicate the potential
for such an approach for the treatment of retinal degeneration
diseases.
Silk for Ocular Wound Healing
The regenerative properties of silk fibroin in ocular tissue en-
gineering can be extended to other ocular treatments, such as
wound healing of the ocular surface. The ocular wound
healing process typically begins by the migration of epithelial
cells to the wound area, followed by the proliferation and
differentiation of the limbal stem cells to replace the damaged
tissue (23). However, in contrast to its action during tissue
engineering, silk fibroin does not act as a substrate for the cells
to differentiate and proliferate during the wound healing pro-
cess, rather, it has a pharmacological effect to direct the adja-
cent healthy epithelial cells towards the wounded area to start
the healing process.
The migration, proliferation and adhesion of the epithelial
cells to a wound area have been demonstrated in vitro using
limbal epithelial cells and a scratch wound assay (23). To ini-
tiate the scratch wound assay, a healthy epithelial cell layer
was generated from limbal epithelial cells. A wounded region
was generated by scratching the cell monolayer, followed by
washing and the addition of fresh growth media with different
concentrations (0.2, 0.4 and 0.5%w/v) of a proprietary solu-
tion of silk-derived protein (Silk Technologies, Ltd. Plymouth,
Minnesota) with PBS as a vehicle control. Cell migration and
proliferation were monitored by time-lapse imaging. To dif-
ferentiate between migration and proliferation, the mitotic
inhibitor hydroxyurea was used to suppress cell growth. Cell
migration rate was highest at 0.4% concentration, followed by
0.2% and then the PBS vehicle control. However, cell migra-
tion was slower with 0.5% silk-derived protein than with PBS
and significantly slower than with 0.2% silk-derived protein.
Cell proliferation significantly increased in the presence of silk-
derived protein relative to control cells. Cell adhesion also
significantly increased for all silk-derived protein concentra-
tions when compared to the PBS control.
The wound healing effect of silk-derived protein was then
assessed in a rabbit corneal injury model (24) (Fig. 2). The
rabbit corneas were denuded of their epithelial layer and then
treated with silk-derived protein at 0.5% and 2.0% concen-
tration as an eye drop formulation; PBS eye drops served as
the control. Across all treatment groups, the rabbits exhibited
>95% corneal surface repair within the first 48 h post treat-
ment, although the rate of repair was highest following treat-
ment with the silk-derived protein. The authors chose to eval-
uate the 0.5% and 2.0% concentrations, even though the
0.5% concentration performed worst in an in vitro cell migra-
tion study (23).
The wound healing effect of silk fibroin has been postu-
lated to have a therapeutic effect on the dry eye disease.
This disease is marked by a destabilisation of the tear film,
which leads to lower tear production and, ultimately, dam-
age to the corneal epithelial cells and loss of the conjuncti-
val goblet cells (25). The authors (25) used a dry eye mouse
model to evaluate the impact of silk fibroin on tear produc-
tion, corneal irregularity score, corneal epithelial cell de-
tachment, density of conjunctival goblet cells and inflam-
matory factors in the lacrimal gland. Dry eye conditions
were simulated in 12-week-old mice by exposing them to
30–40% ambient humidity and injecting them with scopol-
amine hydrobromide for 10 days. The study consisted of
two test groups (treated with either 1 or 5 mg/ml silk fibro-
in solution) and one control group (treated with PBS). All
formulations were delivered in an eye drop format using an
aqueous silk fibroin solution derived from B. mori cocoons.
The dry eye model group (desiccation stress treatment
group) showed a 76% reduction in tear production, with a
16-fold increase in epithelial cell detachment, and a 56% de-
crease in goblet cell density, when compared to the healthy
control group that was not subjected to stress. After a 10-day
treatment with either PBS or 1 or 5 mg/ml silk fibroin, all
groups showed improved tear production: the PBS group
showed 3-fold increase, while both silk fibroin-treated groups
showed a 4-fold increase.
Corneal irregularity returned to baseline after 10 days in all
3 groups, with the fastest rate observed for the silk fibroin
groups. Epithelial cell detachment showed a 94% decrease
in the silk fibroin groups versus a 31% decrease in the PBS
group. The conjunctival goblet cell densities also increased
after treatment with PBS or silk fibroin, but the densities were
greater for the silk fibroin groups than for the PBS group. The
amounts of inflammatory factors (e.g. TNF-α, MMP-2,
MMP-9, ICAM-1, and VCAM-1) were statistically lower in
the silk fibroin treatment groups than in the PBS group or the
control (no treatment) group. The authors concluded that silk
fibroin has the potential to increase tear production in dry eye
disease through an increase in the numbers of conjunctival
goblet cells and an anti-inflammatory effect of silk fibroin in
the lacrimal gland (25).
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Silk for Ocular Drug Delivery
The ability of silk fibroin to self-assemble into hydrogels in an
aqueous solution, coupled with its biocompatibility, makes it
an attractive polymer for ocular drug delivery of macromole-
cules, such as antibodies and other therapeutic proteins
(reviewed in (60)). One example is the incorporation of
bevacizumab, an antibody that inhibits the protein vascular
endothelial growth factor for the treatment of wet age-
related macular degeneration, into a silk hydrogel. Delivery
of this hydrogel into the vitreous of Dutch belted rabbits via
intravitreal injections (27) revealed the potential of silk
hydrogels for ocular drug delivery, including the capacity for
aseptic processing, biocompatibility and sustained-release ca-
pability (27).
Silk fibroin can be assembled into a hydrogel format in
aqueous solutions; therefore, concentrated sterile solutions of
silk fibroin and bevacizumab can be mixed together, followed
by sonication-induced gelation. This process can be per-
formed aseptically and the resulting test article formulations
are sterile and endotoxin-free in accordance with United
States Pharmacopeia guidelines. After injection into the rabbit
vitreous, no differences were noted in the occurrence of ad-
verse events between the rabbits treated with bevacizumab-
loaded hydrogels and the controls, thereby substantiating the
authors’ claim of biocompatibility. Furthermore, the
bevacizumab incorporated into the silk hydrogel showed a
sustained release for 90 days, in contrast to the commercial
solution formulation of bevacizumab, which showed discon-
tinuous release after 30 days.
Lovett and colleagues demonstrated the promising poten-
tial of silk hydrogel as a vitreous drug delivery system (27),
although the need to develop second generation silk hydrogels
appeared likely. First, the silk hydrogel was not completely
transparent in the vitreous, thereby risking the obscuring of
vision. Second, the capacity for silk hydrogel biodegradation
in the vitreous is currently unknown, and the reported obser-
vations are inconclusive because a volume reduction in the silk
hydrogel could occur due to shrinkage rather than biodegra-
dation. The in vitro bevacizumab release profile was better
from the silk hydrogel than from the control (at >33 days),
but the achieved concentration of 500 ng/mL (or less) was
below the therapeutic level required for biological efficacy,
based on published and calculated pharmacokinetics data
(92–95). The in vivo data were also below the therapeutic win-
dow. Based on the in vitro data, the total recovery of
bevacizumab was apparently incomplete.
The total recovery of an encapsulated protein can be af-
fected by many factors related to the interactions of the pro-
tein with the silk fibroin matrix. For instance, Guziewicz and
colleagues found that the cumulative release of a murine IgG1
monoclonal antibody, which is synonymous with its total re-
covery, decreased incrementally with increasing silk fibroin
concentrations in a lyogel formulation (96). Lyogels are
Fig. 2 Impact of silk fibroin-derived protein on the healing of a rabbit corneal wound. (a) Fluorescein signal (i.e. wound area) at indicated time points of rabbit
corneas subjected to epithelial debridement. (b) Corneal wound healing and (c) normalised healing rates between 6 and 24 h post-debridement. Reproduced
with permission from (24).
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lyophilised formulations of self-assembled hydrogels. The in-
crease in silk fibroin concentration directly impacted the den-
sity of the lyogel, which controls the solvent penetration and
disruption of the silk-antibody hydrophobic interactions.
These hydrophobic interactions could be countered by pH
effects and additional, secondary ionic interactions, which,
although weaker, could improve the release and recovery of
the antibody. This study also showed that the silk matrix can
adversely affect an encapsulated antibody containing impor-
tant methionine residues, as oxidation of these residues in-
creased with increasing silk density. Oxidation increased from
6% to 28% with a 3% silk lyogel and to 34% with a 7% lyogel
(96). Although the observed oxidation in this study did not
affect the biological activity of the model protein, such chem-
ical modification has been implicated in adverse effect to other
protein therapeutics and applications (97–99).
In addition to the solution pH, different types of salts and
the ionic strength of a solution can significantly affect the ionic
interactions between a protein drug and its surrounding silk
fibroin matrix (100). Chaotropic salts can disrupt these ionic
interactions, as shown by the inclusion of sodium thiocyanate,
which improved the release of the protein drug. Conversely,
kosmotropic salts, such as sodium sulphate, can entropically
drive the complex coacervation between proteins with oppos-
ing net charges, such as protamine and silk fibroin at neutral
pH.
The ability of silk fibroin to interact ionically with an op-
positely charged molecule can be exploited for topical drug
delivery on the eye surface. For example, Dong and colleagues
utilised the electrostatic interactions between the soluble silk
fibroin and liposomes to develop a formulation for topical
delivery (26). Their objective was to extend the residence time
of ibuprofen on the eye surface by encapsulating it into lipo-
somes coated with silk fibroin. In this application, the silk
fibroin served as a potential mucoadhesive biopolymer to re-
tain the drug on the eye surface to ensure sustained delivery.
The silk fibroin was prepared by degumming B. mori silk
cocoons twice for 20 min in sodium carbonate. After washing
and drying, the collected silk fibroin was dissolved in amixture
of calcium chloride, ethanol and water at a molar ratio of
1:2:8 while stirring at 78°C for 2, 4, 6, and 8 h. The differences
in dissolution time yielded different fractions of silk fibroin
with different molecular weights. After water dialysis, the
resulting silk fibroin solution was lyophilised for 48 h and then
reconstituted to 5% w/v with PBS for preparation of silk fi-
broin coated liposomes. The liposomes containing ibuprofen
were coated with silk fibroin by adding a silk fibroin solution to
a final concentration of 0.5%, 1.0% or 2.0% (w/v). After 1 h of
gentle agitation, methanol was added to induce the structural
transition of the silk fibroin and to precipitate the silk fibroin
coated liposomes for collection and washing.
Gel electrophoresis showed that the molecular weights of
the silk fibroin protein chains decreased as the dissolving time
increased. Fourier-transform infrared spectroscopy and X-ray
diffraction data confirmed beta-sheet formation. In vitro cor-
neal permeation experiments showed that ibuprofen release
was the slowest from silk-coated liposomes, when compared to
uncoated liposomes and an aqueous formulation of ibuprofen.
While the apparent permeability coefficients, derived from the
transport flux of ibuprofen through the thickness of the corne-
al membrane, were the same for all tested formulations, a
sustained permeation was observed for the silk-coated lipo-
some formulation (26). The data suggest that silk fibroin-
coated liposomes could be a potential drug delivery system
for ophthalmic formulations.
Silk for Ocular Prostheses
The transparent property of silk fibroin renders this biopoly-
mer an interesting candidate for use as a corneal prosthesis to
improve visual acuity. Applegate and colleagues generated
elastic silk hydrogels that were chemically crosslinked using
riboflavin (21), a photoinitiator that has been used to crosslink
corneal collagen for treatment of corneal ectatic diseases (101).
These authors examined the mechanisms of silk fibroin
crosslinking by riboflavin and found that the elastic crosslinked
silk hydrogels adhered to the corneal collagen of enucleated
and de-epithelialised porcine eyes. The silk hydrogels main-
tained their 40 μm thickness and adhered to the surface of the
eyes even after extensive washing with PBS. By contrast, the
silk films without riboflavin and silk films containing riboflavin
but not illuminated were both readily washed from the eye
surface. The authors then conducted an in vitro assessment of
the photocrosslinking process using heavy water D2O, sodium
azide and superoxide dismutase and determined that the silk
gelation was driven principally by dityrosine formation
radicalised by the excited riboflavin. The formation of
dityrosine complexes from the tyrosine amino acid residues
covalently bound the silk molecules together to form the
elastic hydrogel (21) (as opposed to physically cross-linked silk
hydrogels, which are brittle (60)).
Crosslinked silk hydrogels can be engineered to mimic na-
ture’s photonic crystals. Min and colleagues evaluated a silk-
based crosslinked hydrogel as an ocular prosthesis for high-
technology applications that include night vision, infrared
vision and in vivo biosensors (22) (Fig. 3). The synthetic pho-
tonic crystals were generated by stacking layers of 300 nm
poly(methyl methacrylate) spheres on a silicon substrate,
followed by photocrosslinking of a silk fibroin and stilbene
solution, which was poured into the layers of the sphere tem-
plate. The silicone substrate was then physically removed and
the spheres were washed away with acetone. The resulting
synthetic silk-based optical nanostructure was a deformable
and conformable silk hydrogel inverse opal (i.e. 3 dimensional
photonic crystal) that displayed an opalescent property under
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white-light illumination in different media, such as air, water
and isopropanol.
The optical properties of the silk hydrogel inverse opal
were the direct effects of the transparent silk fibroin coupled
with the pseudophotonic band gap associated with the lattice
geometry and the reflective index of the media. Min and col-
leagues showed that the pseudophotonic band gap, corre-
sponding to the exhibited structural colour, can be manipu-
lated using mechanical forces, such as stretching and pressure,
to alter the interplanar spacing. For instance, a stretching
strain of 10% induced a 7 nm blue shift of the reflectance
λpeak, while an increase to 20 kPa resulted in an approximately
4 nm blue shift. Using an eye model consisting of hemispheres
of agarose gel and soft contact lenses, the authors showed that
the silk hydrogel inverse opal enhanced the absorption of in-
cident white light in the broad range of 510–660 nm at a
maximum factor of approximately 1.3 (Fig. 3). The observed
optical properties of the silk hydrogel inverse opal showed the
potential for engineered silk hydrogel to serve as an artificial
tapetum lucidum,which also can enhance the incident light avail-
able to the photoreceptors to provide superior night vision
(emulating nocturnal animals) and as a glaucoma indicator
through the detection of intraocular pressure (22).
Silk and the Advanced, Electronically Enhanced Ocular
Drug Delivery Concepts
Silk fibroin is an interesting example of a biological liquid
crystal and it displays long-range partial orientation of molec-
ular motifs. In particular, the molecules are constrained into
parallel planes (smectic A phase symmetry), which imparts
structural strength and flexoelectric properties, where
application of strain generates polarisation in a manner
similar to but distinct from piezoelectricity. Helicoid motifs
are common in biological systems, such as silk, DNA and
cellulose (102) and show layer structures and twists.
Application of strain allows stretching and recovery of silk
fibroin and increasing concentrations of solutions promote
tangling that leads to increases in viscosity before the emer-
gence of crystallinity. These interesting properties bridge the
gap between structural properties and those useful in fabricat-
ing devices that respond to changes in, for example, transpar-
ency or electrical polarisation.
Silk has many potential roles as a material in ocular
applications as it can be processed into a variety of forms
including weavable fibres, as well as films, membranes,
particulates and hydrogels which can be loaded with drugs
and made into responsive systems that would lead to better
control of delivery rates. These systems would fit into the
category of highly biocompatible physical engines capable
of sensing and controlling flux. Koh and colleagues specif-
ically reviewed this need as ‘a ‘green’ approach for
manufacturing next-generation wearable, implantable,
self-resorbable electronics and energy-devices’ (103). This
approach requires natural materials or adapted natural
materials that, in this context, can outperform synthetic
materials. Nanotechnology approaches to modify cast films
(e.g. nano-patterning or nano-sculpturing) must be
complemented with organic semiconductors and energy
sources. Koh and colleagues reviewed the use of high
throughput hot- or room-temperature nanoimprinting
techniques to create sub-100 nm features on silk fibroin
(103). Subsequent treatment of the film with methanol
then causes crystallisation (converting soluble silk I to water
insoluble silk II) and increases the glass transition temper-
ature. This approach can then be used to build photonic
devices, such as diffractive systems, holograms prisms and
microlens arrays (4).
Fig. 3 Deformable and conformable silk fibroin hydrogel three dimensional photonic crystal (i.e. opal). (a) Photographic images showing the reflection behaviour
of a red laser beam in the absence and presence of an opal conformally placed on an agarose gel hemisphere (an artificial eye model). (b) The in silico simulation
reveals that the conformal opal acts as a concave mirror, focusing the reflected light. (c) and (d) Schematic diagram and experiment to prove better absorption of
incident light by opal. Copyright (2017) National Academy of Sciences, reproduced with permission from (22).
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Field effect transistors have extremely high impedance,
so tiny currents can be used to gate a switch (i.e. a transis-
tor). Organic field-effect transistors were described in
1987, although they were largely hybrid inorganic-
organic devices. A polymer has advantages over doped
silicon for electric switching and amplification in terms of
flexibility and the ability to be the construction material for
machines using printing and spin-coating techniques (104).
Silk fibroin can be used as the dielectric and sandwiched
between the gate and conducting layer, thereby replacing
silicon dioxide. Silk fibroin has been used in the fabrication
of diodes, including those which are light-emitting,
allowing transmittance of information though light chan-
nels and films (4). Silk fibroin has also been exploited in the
fabrication of light-sensing or wirelessly powered devices
that allows remote triggering of drug release and monitor-
ing of events deep within body tissues (105), for example
the eye.
Silk fibroin based Bsoft robots^ or devices (106) are intrigu-
ing and have the potential to contribute to advanced
healthcare applications. However, the robotisation of ma-
chines typically requires a memory system containing the in-
struction set. This type of system is generally associated with
some kind of chip, and the chip materials usually far outlast
the use of the device. Bioresorbable electronics based onmono
crystalline silicon have now been described, while organic
substrates as diverse as rice paper, cheese, charcoal, seaweed
and silk fibroin have been reported (reviewed in (107)). For
example, Song and colleagues consider the use of zinc oxide,
magnesium and silk firboin to construct resistive random ac-
cess memory devices, which, at the end of life, would
completely dissolve and be resorbed (108). Resistive random
access memory devices have very low operational voltages and
low power requirements, extremely fast write read speeds, and
are non-volatile and reliable. Carbon-based resistive random
access memory devices are one of the most promising candi-
dates as these use oxygen-based redox reactions in switching
(109). Gorgula and colleagues described a transparent flexible
device constructed from gold nanoparticles embedded in a silk
fibroin matrix with an ON/OFF ratio of resistance of more
than 6 orders of magnitude (110). This was achieved by fila-
mentary switching, a process that involves alteration of the
molecular dimensions of a structure, such as a macromolecule
or polymer. Reputedly, this kind of solid-state device can
model the biological synapse (111).
Unlike silk fibroin, sericin is generally not sufficiently
strong or elastic to make membranes from pure material;
however, it will adhere onto other matrices as a thin film.
For example, Zhang (43) quotes a Japanese patent describ-
ing the production of a distortion-free liquid crystal display
using sericin. Cross-linking the protein improves its physi-
cal stability and the treated protein can be used to make
hydrophilic membranes.
Electric textiles have also been fabricated from a weft
yarn of copper wire wound onto silk fibroin, or carbonised
silk (112), to make wearable electronics. Silk fibroin has
been considered for the fabrication of thin, flexible and
lightweight devices for wearable and implantable systems
(4,107). Microfluidic silk fibroin devices with binary fluid
channels have been produced using sacrificial gelatine
moulding (113). Three-dimensional printing within
nanoclay:silk fibroin gel ‘free-form printing’ allows com-
plex microstructured objects, including silk-based cantile-
vers, to emerge from a submerged granular hydrogel. The
authors propose that these cantilevers could be controlled
through signals sent through silk-based bio-inks (114).
Here, the issue of the electrical resistance must be consid-
ered. Koh and colleagues reviewed the technologies to re-
duce ‘haze’, the low transparency due to scatter, which can
be improved to values associated with glass by reducing the
cross-sectional area of the fibre and by using metal-doped
silks (103). The utility of silk, with its inherent biocompat-
ibility and comfort, has attracted the imagination of the
electronics engineering industry. For example, plasticised
silk electrodes that conform to the skin and are highly
stretchable (115). These materials could be used in the fab-
rication of scleral devices, including supports for sensors,
reservoirs and directing channels.
CONCLUSIONS
While silk has been used as a suture material for millennia, the
advent of recombinant silks and our ability to regenerate the
silk fibroin has opened up numerous applications for silk in the
treatment of eye disorders. The use of the silk biopolymer for
tissue engineering applications has been pursued for several
decades, whereas its use in drug delivery applications has
emerged over the past 10 years. The use of silk fibroin as a
biological active polymer is now gaining momentum. As we
continue to unravel the secrets of silk, we can expect to see
more silk-inspired materials to enter clinical assessment and
eventual clinical use.
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